QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-neutral-on-agios-pharmaceuticals-lowers-price-target-to-20

JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price target from...

 rbc-capital-downgrades-agios-pharmaceuticals-to-sector-perform-lowers-price-target-to-28

RBC Capital analyst Luca Issi downgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Outperform to Sector Perform and lowers th...

 b-of-a-securities-maintains-buy-on-agios-pharmaceuticals-lowers-price-target-to-32

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target...

 leerink-partners-upgrades-agios-pharmaceuticals-to-outperform-lowers-price-target-to-34

Leerink Partners analyst Andrew Berens upgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Market Perform to Outperform and lo...

 goldman-sachs-maintains-neutral-on-agios-pharmaceuticals-lowers-price-target-to-25

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and lowers the price targ...

 hc-wainwright--co-maintains-buy-on-agios-pharmaceuticals-lowers-price-target-to-48

HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price t...

 why-is-agios-pharmaceuticals-stock-sinking-today

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises,...

 agios-pharmaceuticals-says-topline-results-from-rise-up-phase-3-trial-of-mitapivat-for-sickle-cell-disease-met-its-primary-endpoint-of-hemoglobin-response-while-mitapivat-did-not-achieve-statistical-significance-on-the-annualized-rate-of-sickle-cell-pain-crises-compared-to-placebo

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentrati...

 agios-pharmaceuticals-q3-eps-178-beats-191-estimate-sales-12880m-beat-10417m-estimate

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of...

 reported-earlier-agios-pharmaceuticals-receives-chmps-opinion-for-the-new-indication-for-pyrukynd-the-european-commission-will-now-review-the-chmps-opinion-with-the-final-decision-expected-by-early-2026

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceut...

 hc-wainwright--co-reiterates-buy-on-agios-pharmaceuticals-maintains-56-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION